From January to February 2022, affected by the epidemic, the added value of China Meheco Group Co.Ltd(600056) manufacturing industry maintained double-digit growth, 5.4 percentage points higher than that of national industry; Affected by the high base in the same period of last year, the total profit decreased by 17.6% year-on-year; Exports maintained a rapid growth trend, and the export delivery value increased by 24.3% year-on-year, 7.4 percentage points higher than that of national industries.
The added value of pharmaceutical manufacturing industry continued to maintain double-digit growth. Due to the continuous growth of demand caused by the epidemic, from January to February 2022, the added value of pharmaceutical manufacturing industry still maintained rapid growth against the background of last year’s high base, with a year-on-year increase of 12.9%, 5.4 percentage points higher than that of national industries and most manufacturing industries.
The export delivery value maintained a rapid growth trend. Affected by the continuous outbreak of overseas epidemics, the export demand of epidemic prevention materials and products is strong, which supports the rapid growth of the export of pharmaceutical manufacturing industry. From January to February 2022, the export delivery value of pharmaceutical manufacturing industry increased by 24.3% year-on-year. Under the condition of high base last year, it continued to maintain rapid growth, 7.4 percentage points higher than the industrial average level.
The annual benefit will show a downward trend and continue to narrow. Affected by the high base in the same period last year, from January to February 2022, the operating revenue of China Meheco Group Co.Ltd(600056) manufacturing industry increased by 2.3% year-on-year, down 35.4 percentage points from the same period last year; The total profit decreased by 17.6% year-on-year. As last year’s profits continued to be at a high level, the prices of vaccines and other core profit growth points last year fell sharply this year, affecting the profit growth trend of the pharmaceutical manufacturing industry throughout the year. This year, the demand for nucleic acid detection and antigen self-test products of Omicron epidemic has increased greatly, which is a potential growth point of the benefits of the pharmaceutical manufacturing industry.
